⌘K
t
Hikma Pharmaceuticals PLC's Remuneration Committee granted conditional share awards to its Persons Discharging Managerial Responsibility (PDMRs) on 7 April 2026 under the 2023 Long Term Incentive Plan (LTIP) and 2023 Deferred Bonus Plan (DBP). These awards, totaling 859,659 ordinary shares, were based on a share price of £12.71 per share and granted at nil consideration. LTIP (PSP) awards were specifically scaled back by 16.2%.
| Date | 9 Apr 2026 |
| Time | 16:43:34 |
| Category | Director/PDMR dealings |
| ID | 8839Z |
Hikma Pharmaceuticals PLC - Discretionary Share Awards
LONDON, 9 April 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") and the 2023 Deferred Bonus Plan (the "DBP") to Persons Discharging Managerial Responsibility ("PDMRs") of the Company. No consideration was paid for the grant of the awards.
Awards under the LTIP were made on 7 April 2026 based on a price of £12.71 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 7 April 2026, in accordance with the LTIP rules) (the "LTIP Awards"). All LTIP Awards are subject to the continued employment of the PDMR and malus and clawback provisions.
LTIP Performance Share Plan ("PSP") Awards are subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP (PSP) Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP (PSP) Awards are then subject to an additional two-year holding period. LTIP (Conditional) Awards will normally vest on the second anniversary of the date of grant.
Taking into account the recent share price volatility and the absolute and relative fall in the Company's share price since the prior year grant of LTIP Awards, the Remuneration Committee has scaled back the level of the LTIP (PSP) Awards for the PDMRs. The share awards have been reduced by 16.2%, equating to half the share price decline since the prior year LTIP grant. The Remuneration Committee also retains discretion to further adjust award outcomes at vesting to take into account windfall gains if necessary.
Awards under the DBP were made on 7 April 2026 based on a price of £12.71 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 7 April 2026, in accordance with the DBP rules) (the "DBP Awards"). The vesting of the DBP Awards is subject to the continued employment of the PDMRs, and malus and clawback provisions. The DBP Awards will normally vest on the third anniversary of the date of grant.
This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Said Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP and DBP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 158,336 |
||
|
Nil |
DBP Award: 28,149 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 186,485 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Mazen Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Mazen Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Executive Vice Chairman and Deputy CEO, MENA |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP and DBP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 126,364 |
||
|
Nil |
DBP Award: 36,135 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 162,499 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Khalid Nabilsi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Khalid Nabilsi |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Deputy CEO, North America and Europe |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 100,792 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 100,792 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Hussein Arkhagha
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Hussein Arkhagha |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 59,221 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 59,221 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Bassam Kanaan
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Bassam Kanaan |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 88,860 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 88,860 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Susan Ringdal |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 49,502 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 49,502 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Julie Hill
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Julie Hill |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 40,043 |
||
|
d) |
Aggregated information |
Price(s): Nil Volume(s): 40,043 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Hafrun Fridriksdottir
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Hafrun Fridriksdottir |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 87,317 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 87,317 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Sam Park
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Sam Park |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Grant of awards under the LTIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
LTIP (PSP) Award: 61,940 |
||
|
Nil |
LTIP (Conditional) Award: 23,000 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 84,940 |
|
|
e) |
Date of the transaction |
7 April 2026 |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760